Fennec Pharmaceuticals (FENC) Liabilities and Shareholders Equity (2010 - 2025)

Fennec Pharmaceuticals (FENC) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $70.6 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 56.97% year-over-year to $70.6 million; the trailing twelve-month figure through Dec 2025 stood at $211.1 million (down 10.64% YoY), and the FY2025 full-year result was $70.6 million, up 56.97% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $70.6 million, up from $49.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $70.6 million in Q4 2025 and bottomed at $15.6 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $28.0 million (2021), against an average of $36.6 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity plunged 44.63%; it then surged 224.95% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $22.4 million in 2021, then grew by 20.19% to $26.9 million in 2022, then fell by 0.28% to $26.9 million in 2023, then soared by 67.31% to $44.9 million in 2024, then surged by 56.97% to $70.6 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $70.6 million (Q4 2025), $49.3 million (Q3 2025), and $44.9 million (Q2 2025), per Business Quant data.

Peer Comparison